Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Q4 Earnings: These Buy-Rated Stocks Crushed Expectations
The 2025 Q4 earnings cycle keeps rolling along, with overall growth remaining strong. Specifically, these companies knocked it out of the park, with both also sporting a favorable Zacks Rank.
Wall Street Analysts See Cardinal (CAH) as a Buy: Should You Invest?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Best Momentum Stock to Buy for February 13th
LTM, ING and CAH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 13, 2026.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal Health Q2 2026 Review: An Epitome Of Resilience And Earnings Power (Upgrade)
Cardinal Health is upgraded to a buy after Q2 2026 delivered robust revenue, margin expansion, and raised full-year guidance. Q2 revenue grew 19% YoY to $65.6B, with non-GAAP EPS up 36% and broad-based segment strength, especially in pharmaceuticals. Management executed $750M in share repurchases YTD, underscoring commitment to capital return and reducing outstanding shares by 2.5%.
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The $65.6 Billion Secret Wall Street Doesn't Want You to Know About Cardinal Health
Cardinal Health (NYSE: CAH) delivered a decisive second-quarter beat on February 5, 2026, with non-GAAP EPS of $2.63, surpassing the $2.38 consensus estimate by 10.5%.
CAH Q2 Earnings Beat Estimates, '26 EPS View Up, Stock Gains
CAH tops second-quarter fiscal 2026 EPS estimates by 10%, posts strong segment profits, and raises full-year earnings outlook, sending shares higher.
Cardinal Health, Inc. (CAH) Q2 2026 Earnings Call Transcript
Cardinal Health, Inc. (CAH) Q2 2026 Earnings Call Transcript
Compared to Estimates, Cardinal (CAH) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
